GlassScriptPhysician profile
Kiran Nangrani
NPI 1164681102
$15,011.04
in general payments reported to CMS, 2019-2025
43 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $10K · 2021: $2,627 · 2022: $541 · 2023: $595 · 2024: $389 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,943.58 | 2020-2023 | Da Vinci Surgical System |
| Exeltis, USA INC. | $547.20 | 2019-2025 | Slynd |
| Abbvie INC. | $455.93 | 2019-2023 | |
| Pfizer INC. | $182.85 | 2022-2025 | |
| Organon LLC | $163.23 | 2022-2025 | Nexplanon |
| Millicent US INC | $138.31 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Avion Pharmaceuticals | $137.99 | 2019-2022 | |
| Daiichi Sankyo INC. | $108.63 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $90.17 | 2019-2021 | |
| Astellas Pharma US INC | $89.59 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $77.99 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $75.90 | 2019-2021 | |
| Lupin INC. | $63.03 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $62.98 | 2019-2020 | |
| Hologic Sales and Service, LLC | $61.37 | 2019-2024 | Myosure Tissue Removal Device, Novasure |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Nangrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.